Nūhou

He aha ka mea i ʻoi aku ma mua o 300 mau hihia o ka hepatitis acute o ka ʻike ʻole ʻia i nā ʻāina ʻoi aku ma mua o 20 a me nā ʻāpana a puni ka honua? Hōʻike ka noiʻi hou e pili ana i ka super antigen i hoʻokumu ʻia e ka coronavirus hou. Ua paʻi ʻia nā mea i ʻike ʻia ma luna o ka puke pai honua authoritative academic journal "The Lancet Gastroenterology & Hepatology".

Ua hōʻike ʻia nā haʻawina i ʻōlelo ʻia e hiki i nā keiki i loaʻa i ka coronavirus hou ke alakaʻi i ka hoʻokumu ʻana o nā waihona maʻi i loko o ke kino. ʻO ke kikoʻī, ʻo ka hoʻomau mau ʻana o ka coronavirus hou i ka ʻōpū o ka ʻōpū o nā keiki hiki ke alakaʻi i ka hoʻokuʻu pinepine ʻana o nā protein viral i loko o nā cell epithelial intestinal, e hopena i ka hoʻōla ʻana. Hiki ke hoʻopili ʻia kēia hoʻoulu ʻana i ka immune e kahi kumu antigen super i loko o ka protein spike o ka coronavirus hou, e like me ka staphylococcal enterotoxin B a hoʻoulu i ka hoʻoulu ʻana o ka cell T ākea a me ka nonspecific. Ua hoʻopili ʻia kēia super antigen-mediated activation o nā cell immune i loko o ka maʻi multisystem inflammatory ma nā keiki (MIS-C).

ʻO ka mea i kapa ʻia ʻo super antigen (SAg) he ʻano mea hiki ke hoʻāla i ka nui o nā clones cell T a hoʻopuka i kahi pane pale pale ikaika me ka haʻahaʻa haʻahaʻa loa (≤10-9 M). ʻO ka maʻi maʻi multisystem inflammatory i nā keiki i hoʻomaka e loaʻa i ka manaʻo nui i ka hoʻomaka ʻana o ʻApelila 2020. I kēlā manawa, ua komo ka honua i ka maʻi maʻi kalaunu hou, a ua nui nā ʻāina i hōʻike i kahi "maʻi ʻē a nā keiki", i pili nui i ka lei aliʻi hou. maʻi virus. ʻO ka hapa nui o nā poʻe maʻi e ʻike i nā hōʻailona e like me ke kuni, ka ʻūlū, ka luaʻi ʻana, ka pehu o ka ʻāʻī lymph nodes, nā lehelehe ʻokiʻoki, a me ka maʻi maʻi, e like me ka maʻi Kawasaki, ʻike ʻia hoʻi ʻo Kawasaki-like maʻi. ʻO ka maʻi maʻi multisystem inflammatory i nā keiki ka nui o 2-6 mau pule ma hope o ka maʻi lei aliʻi hou, a ʻo ka makahiki o ka hoʻomaka ʻana o nā keiki e ʻike ʻia ma waena o 3-10 mau makahiki. ʻOkoʻa ka maʻi ʻeha multisystem i nā keiki mai ka maʻi Kawasaki, a ʻoi aku ka ʻino o ka maʻi i nā keiki i ʻike maikaʻi ʻia no COVID-19.

Ua ʻimi ka poʻe noiʻi ʻo ka maʻi hepatitis i ʻike ʻole ʻia i nā keiki i loaʻa mua i ka maʻi coronavirus hou, a ua loaʻa nā keiki i ka adenovirus ma hope o ka puka ʻana o ka waihona maʻi i loko o ka ʻōpū.

Hōʻike nā mea noiʻi i kahi kūlana like i nā hoʻokolohua ʻiole: ʻO ka maʻi Adenovirus e hoʻoulu i ka staphylococcal enterotoxin B-mediated toxic shock, e alakaʻi ana i ka hāʻule o ka ate a me ka make i nā ʻiole. Ma muli o ke kūlana o kēia manawa, ʻōlelo ʻia ka nānā ʻana o COVID-19 i loko o ka waihona o nā keiki me ka maʻi hepatitis. Inā ʻike ʻia nā hōʻike o ka SARS-CoV-2 superantigen-mediated immune activation, pono e noʻonoʻo ʻia ka immunomodulatory therapy i nā keiki me ka maʻi hepatitis acute.